Tag: disease

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

SAN FRANCISCO, June 24, 2026 /PRNewswire/ -- The global digital health market is expected to witness significant expansion over the coming years, with the...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Investors who lost money in WGS after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

40% more AI per gallon for excellent field performance and greater flexibilityBEIJING, China and TEL AVIV, Israel, June 24, 2026 /PRNewswire/ --  ADAMA Ltd....

Shop BudPop's THCA flower for sale: 15 organically grown, Farm Bill compliant, lab-tested indoor strains with up to 25% THCA.

BURLINGTON, ON, June 23, 2026 /CNW/ - SIR Royalty Income Fund (TSX: SRV.UN) (the "Fund") today announced that SIR Corp. ("SIR" or the "Company"),...